Shield Therapeutics plc
Status: Publicly traded
Direct answer
Shield Therapeutics plc is publicly traded on LSE under the ticker STX.L.
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Can you invest in Shield Therapeutics plc?
Yes. Shield Therapeutics plc trades publicly on LSE as STX.L.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Shield Therapeutics plc
Detailed equity research is provided by MarketSnap.